leadf
logo-loader
viewBetterLife Pharma Inc

BetterLife transitioning to pure-play biotech by acquiring coronavirus therapy with planned merger

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian tells Proactive the firm is working towards becoming a pure-play biotechnology company by merging with privately-held Altum Pharmaceuticals Inc.

Doroudian says under the merger, BetterLife will acquire worldwide rights to commercialize and sell Altum's lead product AP-003, an inhalation formulation that could represent a potential treatment against the coronavirus.

Quick facts: BetterLife Pharma Inc

Price: 0.6358 USD

OTCQB:BETRF
Market: OTCQB
Market Cap: $11.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

BetterLife Pharma reveals clinical trial updates on its treatment for...

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian updates Proactive on the group's clinical trials progress, revealing it has engaged the clinical research organization Pharmaceutical Solutions Ltd to manage its study of AP-003 as a treatment for mild-to-moderate...

1 week ago

2 min read